webinar recording available - register to watch

How will AI transform the future of medicine?

Artificial intelligence (AI) has the potential to solve many of humanity’s problems at a pace that far exceeds the limitations of human intelligence. AI excels at detecting errors, minimizing bias, and accelerating decision-making.

Medicine is one industry that can benefit the most from AI. For example, the patient journey today involves trial and error from diagnoses through treatment; similarly, clinical drug development necessitates human experimentation. Fortunately, AI is improving the status quo, from aiding more accurate diagnoses to enabling smaller placebo arm sizes in clinical trials. But computer science experts say we’re only at the beginning of realizing AI’s full potential.

In this Endpoints webinar, hear from AI researcher Charles Fisher, founder and CEO of Unlearn, about the increasingly prominent role of AI medicine. Unlearn was founded to advance AI to eliminate trial and error in medicine, starting with their prognostic digital twins used in clinical trials today and with broader future applications in personalized medicine.

WHAT WILL BE COVERED IN THIS WEBINAR:
  • Reviewing the current landscape of AI in medicine
  • Discussing some of the most transformative AI applications in the future
  • Providing a potential roadmap connecting the present and future of AI
WHO SHOULD ATTEND THIS WEBINAR:
  • AI/Machine Learning experts and enthusiasts in Pharma and Tech and at Life Sciences VCs
watch now
watch the webinar

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom registration page.

Charles Fisher

Charles Fisher

Founder & CEO, Unlearn.AI

Charles is a scientist with interests at the intersection of physics, machine learning, and computational biology. Previously, Charles worked as a machine learning engineer at Leap Motion and a computational biologist at Pfizer. He was a Philippe Meyer Fellow in theoretical physics at École Normale Supérieure in Paris, France, and a postdoctoral scientist in biophysics at Boston University. Charles holds a Ph.D. in biophysics from Harvard University and a B.S. in biophysics from the University of Michigan.

ArsalanArif
moderator

Arsalan Arif

Founder & Publisher, Endpoints News

Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.